eXoZymes lasse.g@exozymes.com https://exozymes.twentythree.com en-us Visualplatform http://blogs.law.harvard.edu/tech/rss eXoZymes episodic no https://exozymes.twentythree.com/files/rv0.0/sitelogo.gif https://exozymes.twentythree.com http://exozymes.twentythree.com/webull-biotech-sector-webinar-by <p><p>This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing platform and its ability to manufacture rare natural molecules at industrial scale. <br><br>EXOZ Chief Commercial Officer Damien Perriman highlights NCT as the company’s lead proof-of-concept, reviews successful preclinical and manufacturing milestones, and outlines a dual commercialization strategy combining near-term nutraceutical revenues with longer-term pharmaceutical development. <br><br>The presentation also discusses the platform’s broader applicability to additional molecule classes, including cannabinoids, upcoming commercialization milestones, and eXoZymes’ strategy to build a repeatable, capital-efficient engine for developing multiple high-value products.</p></p><p><a href="http://exozymes.twentythree.com/webull-biotech-sector-webinar-by"><img src="http://exozymes.twentythree.com/64968556/129027662/f9b24833907c085946900c5a57681122/standard/download-23-thumbnail.jpg" width="600" height="338"/></a></p> http://exozymes.twentythree.com/photo/129027662 Tue, 30 Jun 2026 15:30:58 GMT Webull 'Biotech Sector' webinar by Perriman This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing platform and its ability to manufacture rare natural molecules at industrial scale. EXOZ Chief Commercial Officer Damien Perriman highlights NCT as the company’s lead proof-of-concept, reviews successful preclinical and manufacturing milestones, and outlines a dual commercialization strategy combining near-term nutraceutical revenues with longer-term pharmaceutical development. The presentation also discusses the platform’s broader applicability to additional molecule classes, including cannabinoids, upcoming commercialization milestones, and eXoZymes’ strategy to build a repeatable, capital-efficient engine for developing multiple high-value products. This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing platform and its ability to manufacture rare natural molecules at industrial scale. EXOZ Chief Commercial Officer Damien Perriman highlights NCT as the... eXoZymes 18:45 <p><p>This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing platform and its ability to manufacture rare natural molecules at industrial scale. <br><br>EXOZ Chief Commercial Officer Damien Perriman highlights NCT as the company’s lead proof-of-concept, reviews successful preclinical and manufacturing milestones, and outlines a dual commercialization strategy combining near-term nutraceutical revenues with longer-term pharmaceutical development. <br><br>The presentation also discusses the platform’s broader applicability to additional molecule classes, including cannabinoids, upcoming commercialization milestones, and eXoZymes’ strategy to build a repeatable, capital-efficient engine for developing multiple high-value products.</p></p><p><a href="http://exozymes.twentythree.com/webull-biotech-sector-webinar-by"><img src="http://exozymes.twentythree.com/64968556/129027662/f9b24833907c085946900c5a57681122/standard/download-23-thumbnail.jpg" width="600" height="338"/></a></p> http://exozymes.twentythree.com/exozymes-second-quarter-2025-update-2 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-second-quarter-2025-update-2"><img src="http://exozymes.twentythree.com/64968578/115195290/8f97577760e6fd5da180ca06bb4455e8/standard/download-33-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/115195290 Wed, 13 Aug 2025 15:31:33 GMT eXoZymes second quarter 2025 update eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session. eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM... eXoZymes 01:04:31 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-second-quarter-2025-update-2"><img src="http://exozymes.twentythree.com/64968578/115195290/8f97577760e6fd5da180ca06bb4455e8/standard/download-33-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/exozymes-first-quarter-2025-and-1 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-first-quarter-2025-and-1"><img src="http://exozymes.twentythree.com/64968576/112708602/383944150b0eca215b2b01b2ec49498f/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112708602 Mon, 19 May 2025 00:27:25 GMT eXoZymes first quarter 2025 and subsidiary NCTx update eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session. eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM... eXoZymes 47:13 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-first-quarter-2025-and-1"><img src="http://exozymes.twentythree.com/64968576/112708602/383944150b0eca215b2b01b2ec49498f/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/exozymes-4th-quarter-and-full-year-4 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday April 2, 2025 at 1:30PM Pacific Time to discuss its results for the fourth quarter and full year 2024.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.&nbsp;</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-4th-quarter-and-full-year-4"><img src="http://exozymes.twentythree.com/64968561/111600181/976e892b681367c8d34914976c8ff16d/standard/download-26-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/111600181 Thu, 03 Apr 2025 15:16:22 GMT eXoZymes 4th quarter and full year 2024 results conference call @ Wednesday... eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday April 2, 2025 at 1:30PM Pacific Time to discuss its results for the fourth quarter and full year 2024. Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday April 2, 2025 at 1:30PM Pacific Time... eXoZymes 48:33 <p><p><strong>eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday April 2, 2025 at 1:30PM Pacific Time to discuss its results for the fourth quarter and full year 2024.</strong></p> <p>&nbsp;</p> <p>Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.&nbsp;</p> </p><p><a href="http://exozymes.twentythree.com/exozymes-4th-quarter-and-full-year-4"><img src="http://exozymes.twentythree.com/64968561/111600181/976e892b681367c8d34914976c8ff16d/standard/download-26-thumbnail.jpg" width="75" height=""/></a></p>